EP1019071A4 - Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods - Google Patents

Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods

Info

Publication number
EP1019071A4
EP1019071A4 EP98922385A EP98922385A EP1019071A4 EP 1019071 A4 EP1019071 A4 EP 1019071A4 EP 98922385 A EP98922385 A EP 98922385A EP 98922385 A EP98922385 A EP 98922385A EP 1019071 A4 EP1019071 A4 EP 1019071A4
Authority
EP
European Patent Office
Prior art keywords
git
gastro
bind
intestinal tract
related methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98922385A
Other languages
German (de)
French (fr)
Other versions
EP1019071A2 (en
Inventor
Vernon L Alvarez
Daniel J O'mahony
Imelda J Lambkin
Catherine A Patterson
Judith Singleton
Benjamin A Belinka Jr
John M Carter
Gerard M Cagney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Cytogen Corp
Original Assignee
Elan Corp PLC
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC, Cytogen Corp filed Critical Elan Corp PLC
Publication of EP1019071A2 publication Critical patent/EP1019071A2/en
Publication of EP1019071A4 publication Critical patent/EP1019071A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP98922385A 1997-05-15 1998-05-15 Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods Withdrawn EP1019071A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4659597P 1997-05-15 1997-05-15
US46595P 1997-05-15
PCT/US1998/010088 WO1998051325A2 (en) 1997-05-15 1998-05-15 Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods

Publications (2)

Publication Number Publication Date
EP1019071A2 EP1019071A2 (en) 2000-07-19
EP1019071A4 true EP1019071A4 (en) 2003-07-30

Family

ID=21944305

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98922385A Withdrawn EP1019071A4 (en) 1997-05-15 1998-05-15 Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods

Country Status (6)

Country Link
EP (1) EP1019071A4 (en)
JP (1) JP4129298B2 (en)
AU (1) AU755154B2 (en)
CA (1) CA2290756A1 (en)
NZ (1) NZ501110A (en)
WO (1) WO1998051325A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
AU1174400A (en) * 1998-11-19 2000-06-13 Elan Corporation, Plc Retro-inversion peptides that target git transport receptors and related methods
AU1174300A (en) * 1998-11-19 2000-06-13 Elan Corporation, Plc Antibodies to peptides that target git receptors and related methods
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
EP1157275A4 (en) * 1999-02-28 2003-01-15 Univ Washington Novel transduction molecules and methods for using same
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
ATE363074T1 (en) 1999-09-14 2007-06-15 Xenoport Inc SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
AU7839700A (en) 1999-09-29 2001-04-30 Ronald W. Barrett Compounds displayed on replicable genetic packages and methods of using same
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
JP4387669B2 (en) 2000-10-13 2009-12-16 ザイジェン エス．アー． Intracellular delivery of biological effectors with novel transporter peptide sequences
WO2002077182A2 (en) 2001-03-21 2002-10-03 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
EP1432729B1 (en) * 2001-07-02 2008-11-12 Merrion Research III Limited Peyers's patch and/or m-cell targeting ligands
GB0223737D0 (en) * 2002-10-11 2002-11-20 Plant Bioscience Ltd A Promoter from streptomyces coelicolor
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2652280C (en) * 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
KR100866925B1 (en) 2006-08-28 2008-11-04 주식회사 인실리코텍 Enterocyte-Transcytotic peptide identified by the Peroral Pharge Display Process and Peroral drug delivery systems using the same
WO2008084899A1 (en) * 2007-01-10 2008-07-17 Insilicotech Co., Ltd. The enterocyte-transcytotic, tissue target and m cell target peptide identified by the phage display process and drug delivery systems using the same
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
JP2011500569A (en) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー Vaccine nanotechnology
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP2020534261A (en) * 2017-09-08 2020-11-26 ザ ユニバーシティ オブ ブリストル Protein delivery to the membrane

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017613A1 (en) * 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998051825A1 (en) * 1997-05-15 1998-11-19 Elan Corporation, Plc Peptides which enhance transport of an active agent across tissues and compositions and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
SE9401460D0 (en) * 1994-04-28 1994-04-28 Ferring Ab Antigen / antibody specificity exhanger

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017613A1 (en) * 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998051825A1 (en) * 1997-05-15 1998-11-19 Elan Corporation, Plc Peptides which enhance transport of an active agent across tissues and compositions and methods of using the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHANTRET I ET AL: "SEQUENCE OF THE COMPLETE CDNA AND THE 5' STRUCTURE OF THE HUMAN SUCRASE-ISOMALTASE GENE. POSSIBLE HOMOLOGY WITH A YEAST GLUCOAMYLASE", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 285, no. 3, 1992, pages 915 - 923, XP000909979, ISSN: 0264-6021 *
DANTZIG ANNE H ET AL: "Association of intestinal peptide transport with a protein related to the cadherin superfamily.", SCIENCE (WASHINGTON D C), vol. 264, no. 5157, 1994, pages 430 - 433, XP001121129, ISSN: 0036-8075 *
LAMBKIN ET PINILLA: "Targeting approaches to oral drug delivery.", EXPERT OPINION ON BIOLOGICAL THERAPY. ENGLAND JAN 2002, vol. 2, no. 1, January 2002 (2002-01-01), pages 67 - 73, XP002229897, ISSN: 1471-2598 *
LAMBKIN I ET AL: "IDENTIFICATION AND CHARACTERISATION OF PEPTIDES WHICH FACILITATE TRANSPORT ACROSS CACO-2 CELL MONOLAYERS FROM A RANDOM PHAGE DISPLAY LIBRARY", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 11, November 1997 (1997-11-01), pages 667, XP000915523, ISSN: 0724-8741 *
LAMBKIN I ET AL: "IN VITRO SELECTION OF PEPTIDES WHICH FACILITATE TRANSPORT ACROSS ISOLATED RAT COLON MUCOSAE FROM RANDOM PHAGE DISPLAY LIBRARIES", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 11, November 1997 (1997-11-01), pages S - 645, XP000915519, ISSN: 0724-8741 *
LEE W S ET AL: "CLONING AND CHROMOSOMAL LOCALIZATION OF A HUMAN KIDNEY CDNA INVOLVED IN CYSTINE, DIBASIC, AND NEUTRAL AMINO ACID TRANSPORT", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 91, no. 5, 1993, pages 1959 - 1963, XP000910010, ISSN: 0021-9738 *
See also references of WO9851325A3 *
STEVENSON C L ET AL: "PERMEABILITY SCREEN FOR SYNTHETIC PEPTIDE COMBINATORIAL LIBRARIES USING CACO-2 CELL MONOLAYERS AND LC/MS/MS", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 12, no. 9, SUPPL, September 1995 (1995-09-01), pages S94,ANBIOTEC2064, XP009000612, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
EP1019071A2 (en) 2000-07-19
JP2002504811A (en) 2002-02-12
AU7494398A (en) 1998-12-08
WO1998051325A2 (en) 1998-11-19
CA2290756A1 (en) 1998-11-19
WO1998051325A3 (en) 1998-12-17
AU755154B2 (en) 2002-12-05
JP4129298B2 (en) 2008-08-06
NZ501110A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
EP1019071A4 (en) Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
ZA9711045B (en) Peptides and compounds that bind to a receptor
ZA964814B (en) Peptides and compounds that bind to a receptor.
ZA95788B (en) Peptides and compounds that bind to the IL-1 receptor
IL178471A0 (en) Kappa receptor opioid peptides and compositions comprising them
ZA981423B (en) Improvements in transport accommadation
EP1030910A4 (en) Anti-***e catalytic antibody
EP0838472A4 (en) Peptides binding to low-density lipoproteins
IL133602A0 (en) Protein that binds trail
HUP9904199A3 (en) Anti-p53 single-chain antibody fragments and their uses
GB9718110D0 (en) Peptides
PL352064A1 (en) Peptides from the tt virus sequence and monospecific antibodies binding to the tt virus
GB9918155D0 (en) Proteins and peptides
EP0996626A4 (en) Glycine transporter
GB9721251D0 (en) Wrapping materials
GB9700154D0 (en) Peptides
EP0996457A4 (en) Fsh-releasing peptides
EP1302477A4 (en) Peptide fructose and complex thereof with binding protein
EP1313505A4 (en) Hla binding peptides and their uses
AU1174300A (en) Antibodies to peptides that target git receptors and related methods
GB9712383D0 (en) Peptides and compounds that bind to the IL-5 receptor
GB9722574D0 (en) Human glycine transporter protein
TW333938U (en) Multi-size suitable cargo stillage
GB9806260D0 (en) Round bale transporter
GB9706556D0 (en) Peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/705 B

Ipc: 7A 61K 9/51 B

Ipc: 7C 07K 5/10 B

Ipc: 7A 61K 38/09 B

Ipc: 7A 61K 38/28 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030613

17Q First examination report despatched

Effective date: 20040206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040817